Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 earnings results
Ligand Pharmaceuticals Incorporated (LGND) reported Q3 2026 results on Oct 29, 2026, 7:14:44 AM ET: adjusted EPS $2.67 vs. $2.33 expected (beat by 14.7%); revenue $78.70M vs. $77.23M expected (beat by 1.9%). Outlook: Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $2.67 | $2.33 | Beat by 14.7% |
| Revenue | $78.70M | $77.23M | Beat by 1.9% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Oct 29, 2026, 7:14:44 AM ET. Nexqual published them 40 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue fell 31.8% from $115.46M.
Stock reaction
The results came out before the market opened. LGND closed at $317.33 on October 29, 2026, down 0.5% from its $318.78 close on October 28, 2026 before the results.
Questions and answers
Did Ligand Pharmaceuticals Incorporated beat earnings expectations?
Yes. Ligand Pharmaceuticals Incorporated reported adjusted EPS of $2.67 against an average analyst estimate of $2.33 (beat by 14.7%), and revenue of $78.70M against $77.23M expected (beat by 1.9%).
What were Ligand Pharmaceuticals Incorporated's Q3 2026 earnings and revenue?
adjusted diluted EPS of $2.67 and revenue of $78.70M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue fell 31.8% from $115.46M.
When did Ligand Pharmaceuticals Incorporated report Q3 2026 earnings?
Oct 29, 2026, 7:14:44 AM ET, in an SEC 8-K filing (Item 2.02).
How did LGND stock react to the earnings?
The results came out before the market opened. LGND closed at $317.33 on October 29, 2026, down 0.5% from its $318.78 close on October 28, 2026 before the results.
What did Ligand Pharmaceuticals Incorporated say about its outlook?
Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75.
More on LGND
LGND stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built October 29, 2026 at 23:08 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt